BWX’s (NYSE:BWXT) Q2 CY2026 Earnings Results: Revenue In Line With Expectations

BWX (NYSE:BWXT) reported Q2 CY2026 revenue of $901.6 million, up 18% year on year and in line with Wall Street expectations. Non-GAAP adjusted EPS was $1.07, up from $1.02, beating consensus by 2.7%. Analysts expect revenue growth of 13.4% and full-year EPS to rise from $4.27 to $4.99.

Original reporting
Published Aug 3, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BWX’s (NYSE:BWXT) Q2 CY2026 Earnings Results: Revenue In Line With Expectations — source image
Decision brief

The 30-second read

$BWXTNeutralMed
01

Why it matters

Q2 showed strong YoY growth and a modest EPS beat, but the market reaction was negative, implying investors wanted more revenue upside or clearer margin improvement. Forward-looking analyst expectations point to decelerating revenue growth, which may cap near-term multiple expansion.

02

Market read

Traders can reassess near-term expectations for BWXT based on the mix of in-line revenue, EPS beat, stable Q2 operating margin, and decelerating forward revenue growth assumptions.

03

What to watch

The article flags a multi-year operating margin decline (down 4.3pp over five years), which could be the real driver of the selloff despite the quarter’s stability.

Relevance 8/10Novelty 7/10Timing: after-hours/after-results reaction, stock traded down 3.6% to $167.85 immediately following results

Background

BWX (BWXT) is a nuclear components and fuel supplier for government and commercial customers, with revenue split largely between Government Operations and Commercial Operations.

Company-level read

Ticker impact

$BWXTNeutralMedium confidence
Context

BWX reported Q2 CY2026 revenue of $901.6M (+18% YoY) and adjusted EPS of $1.07, beating consensus by 2.7%.

Expected impact

Near-term volatility likely persists as investors weigh the revenue in-line outcome versus the EPS beat and the guidance mix.

Evidence & confidence

The article provides hard datapoints (revenue, adjusted EPS, beat vs estimates, and immediate post-results move) but does not include detailed forward guidance beyond analyst expectations and a brief EBITDA guidance comment.

Market effects

Nuclear components and defense industrials read-through: stable operating margin and strong government growth support the segment’s demand narrative.

Primarily US defense supply chain sentiment, with limited explicit regional spillover in the text.

Limited global linkage stated; the article frames demand via government and commercial operations rather than international contracts.

Counterpoint

The revenue was in-line, but the EPS beat and stable Q2 operating margin suggest the market may be over-penalizing the lack of upside on top-line.

Key entities

  • BWX

    BWX (BWXT) reported Q2 CY2026 results with revenue $901.6M (+18% YoY) and adjusted EPS $1.07 (2.7% above consensus).

  • Wall Street estimates

    Revenue was described as in line with expectations; adjusted EPS beat by 2.7%. Analysts also expect revenue growth of 13.4% over the next 12 months.

Related articles

$BWXTMed

BWXT expands U.S. naval nuclear manufacturing base through PCG acquisition, targeting capacity and supply-chain gains for Navy programs

BWXT said it completed its early-July acquisition of PCG, expanding its U.S. naval nuclear manufacturing base. BWXT’s CEO Rex Geveden said most PCG revenue and backlog supports the U.S. Naval Nuclear Propulsion Program. BWXT plans integration over coming quarters, assessing which outsourced work to bring in-house and potential capital needs, with PCG focused on medium-scale components.

$BWXTMedAI 8/10

Sweden: Nordic Capital to acquire majority stake in BWXT’s medical business

BWX Technologies (NYSE: BWXT) will sell its medical business, including BWXT Medical and Kinectrics’ stable medical isotopes unit, to Sweden-based Nordic Capital for up to $800m. BWXT will keep a minority stake and continue providing isotope and radiochemical expertise. BWXT said the business tripled revenue since 2018; Nordic Capital plans to scale radiopharmaceuticals.

$BWXTHighAI 9/10

BWX Technologies, Inc. (BWXT): Results of Operations and Financial Condition

BWX Technologies, Inc. (BWXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bwxt_63026xerexhibit991.htm EX-99.1 Document BWX Technologies Reports Second Quarter 2026 Results • 2Q26 revenues of $901.6 million • 2Q26 net income of $89.1 million, adjusted EBITDA (1) of $155.5 million • 2Q26 diluted GAAP EPS of $0.97, non-GAAP (1) EPS of $1.07 • An

$BWXTMed

JPMorgan makes bold BWX Technologies prediction

JPMorgan began coverage of BWX Technologies (BWXT) on July 27, 2026 with an Overweight rating and a $230 price target through Dec 2027. The target is about 30% above the stock’s July 28 close of $169.67. JPMorgan cites BWXT’s U.S. Navy reactor-core work, $1.4B in new Navy contracts in May, and Q1 FY2026 results: $860.2M revenue (+26% YoY) and $1.12 adjusted EPS.